



EUROPEAN
COMMISSION

Brussels, **XXX**
PLAN/974/2025 ANNEX
(POOL/E4/2025/974/974-EN
ANNEX.docx)
[...](2025) **XXX** draft

ANNEX

ANNEX

to the

COMMISSION IMPLEMENTING REGULATION (EU) .../...

**renewing the approval of dazomet as an active substance for use in biocidal products of
product-type 8 in accordance with Regulation (EU) No 528/2012 of the European
Parliament and of the Council**

ANNEX

| Common Name | IUPAC Name Identification Numbers | Minimum degree of purity of the active substance ¹ | Expiry date of approval | Product type | Specific conditions |
|-------------|---|--|-------------------------------|-----------------|--|
| Dazomet | Tetrahydro-3,5- dimethyl-2H-1,3,5- thiadiazine-2-thione EC No: 208-576-7 CAS No: 533-74-4 | 96 % weight/weight | 31 August 2040 | 8 | <p>1) The authorisation of biocidal products containing dazomet as an active substance is subject to the following conditions:</p> <p>(a) the product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level assessment of the active substance;</p> <p>(b) Member States' competent authorities or, in the case of a Union authorisation, the Commission, shall specify in the summary of the biocidal product characteristics the relevant instructions for use and precautions to be indicated on the label of the treated articles under Article 58(3), second subparagraph, point (e), of Regulation (EU) No 528/2012.</p> <p>2) The placing on the market of treated articles is subject to the following condition: as from 1 March 2026, the person responsible for the placing on the market of a treated article treated with or incorporating dazomet shall ensure that the label of that treated article provides the information listed in Article 58(3), second subparagraph, of Regulation (EU) No 528/2012.</p> |

¹ The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product made available on the market may be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.